Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 13/20 | 0.49 |
| ▸ | AR | P10275 | 5/20 | 0.45 |
| ▸ | PGR | P06401 | 3/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | SHBG | P04278 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1897274 | 1.00 | CYP19A1 (0.49) | CYP19A1ARPGRNR3C2SHBG | |
| SCHEMBL4588011 | 1.00 | CYP19A1 (0.49) | CYP19A1ARPGRNR3C2SHBG | |
| SCHEMBL6376819 | 0.89 | CYP19A1 (0.52) | CYP19A1ARPGRNR3C2SHBG | |
| SCHEMBL4586771 | 0.86 | AR (0.50) | CYP19A1ARPGRNR3C2SHBG | |
| SCHEMBL14342102 | 0.86 | AR (0.50) | CYP19A1ARPGRNR3C2SHBG | |
| SCHEMBL4588578 | 0.86 | CYP19A1 (0.49) | CYP19A1ARPGRNR3C2SHBG | |
| SCHEMBL10943281 | 0.85 | CYP19A1 (0.46) | CYP19A1ARPGRNR3C2SHBG | |
| SCHEMBL4588291 | 0.85 | CYP19A1 (0.45) | CYP19A1ARPGRNR3C2 | |
| SCHEMBL10947171 | 0.84 | CYP19A1 (0.47) | CYP19A1ARPGRNR3C2SHBG | |
| SCHEMBL908750 | 0.82 | CYP19A1 (0.64) | CYP19A1PGRSHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156843-A1 | PROCESS FOR AROMATIZING 19-NORANDROST-4-EN-3-ONES TO ESTRA-1,3,5(10)-TRIENES | BAYER SCHERING PHARMA AG (DE) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156843-A1 | PROCESS FOR AROMATIZING 19-NORANDROST-4-EN-3-ONES TO ESTRA-1,3,5(10)-TRIENES | CYP19A1, HSD17B11, NR5A1 | CYP19A1 1/4885AR 19/4885PGR 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.